カナダの専門薬局市場 – 業界動向と2030年までの予測

カナダの専門薬局市場の分析と規模

専門薬局のモデルは、慢性疾患や複雑な病状を持つ患者に包括的で調整されたケア モデルを提供し、優れた臨床的および経済的成果を達成し、患者のケアへのアクセスを迅速化することを目的としています。専門薬局は、重病の患者にその病状に合わせて処方された薬を提供し、これらの薬に必要な患者ケア サービスを提供して、人生を変え、時には命を救うこともあるが、多くの場合は高額な薬に対する償還問題に直面している患者をサポートします。

高齢者人口の増加がこの分野の成長を牽引すると予想されています。しかし、厳格な規制枠組みがカナダの専門薬局市場の成長を妨げると予想されています。

Data Bridge Market Research の分析によると、カナダの専門薬局市場は、予測期間中に 11.3% の CAGR で成長し、2030 年までに 141 億 9,250 万米ドルに達すると予想されています。カナダの専門薬局市場では、臨床サービスが最大のセグメントを占めています。

Market Definition

Specialty pharmacies differ from traditional pharmacies in that they coordinate many aspects of patient care and disease management. They are intended to deliver medications with special handling, storage, and distribution requirements in a standardized manner that allows for economies of scale. Specialty pharmacies are also intended to improve clinical and economic outcomes for patients suffering from complex, often chronic, and rare conditions, with close contact and management by clinicians. Specialty pharmacies employ healthcare professionals who educate patients, help ensure appropriate medication use, promote adherence, and try to avoid unnecessary costs. Other support systems coordinate information sharing among clinicians treating patients and assist patients in locating resources to help with out-of-pocket expenses.

Canada Specialty Pharmacy Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:

Drivers/Opportunities

• Increasing prevalence of chronic and rare diseases

With the rising economic growth, people are more interested in long-term health and wellness. Patients with chronic diseases need to monitor their health on a regular basis. Specialty pharmacy services help manage chronic and rare diseases due to the availability of specialty drugs for chronic diseases such as diabetes, heart failure or chronic obstructive pulmonary disease (COPD), cancer, and rare diseases such as autoimmune disorders, namely eosinophilic granulomatosis with polyangiitis (EGPA), Guillain-Barre syndrome, Kawasaki disease among others. Its service includes medication dispensing and providing other healthcare assistance.

• Increasing geriatric population

As the geriatric population is more prone to chronic disease and injuries, the prevalence rate of their diseases and injuries in Canada leads to demand for specialty pharmacy services to monitor and care for their health. Therefore, the geriatric population and its rising disease rates play a major role in driving the specialty pharmacy market. These services use a unique combination of digital tools and compassionate clinical services to deliver fertility medication, nurse-administered home infusions, and care for people living with everything from rheumatoid arthritis, cancer, and HIV to the rarest of rare conditions.

• Emerging markets of specialty pharmacies

A major factor in the growth of the specialized pharmacy market is the aging population. Diabetes due to an unhealthy lifestyle and rising dementia, Alzheimer's, and Parkinson's diseases are common in the geriatric population. From 2015 to 2021, the number of seniors is projected to exceed the number of children aged 14 and younger for the first time. By 2036, seniors could reach between 9.9 and 10.9 million people. According to a medium-growth scenario, the number of people aged 80 and older is expected to double to 3.3 million by 2036. The population aged 100 and older could triple to more than 20,000. Apart from the geriatric population, GDP, population density, and improving access to the specialized pharmacy market create growth opportunities.

Restraints/Challenges

• Stringent regulatory framework

Canada's federal and provincial governments jointly set their pharmaceutical policy. The federal government is in charge of protecting producers' intellectual property rights (patents), initial approval, labelling, and overall market competition for prescription medications. The provincial government is in charge of and has authority over financing all medical services, including prescription drugs. Moreover, specialty drugs come under high-risk drugs, including those for chronic diseases such as cancer and rare diseases such as autoimmune diseases. Therefore, there are different sets of regulatory frameworks for the distribution as well as manufacturing of these drugs.

• Insufficient funding for specialty pharmacies

The mortality ratio due to chronic diseases is very high in the Canadian region. One of the major reasons for this is the insufficient funding for specialty pharmacies which leads to a decrease in the number of specialty pharmacies.

Specialty pharmacies deal with specialty drugs for chronic diseases and rare diseases. A specialty pharmacy is a state-licensed pharmacy that solely or largely provides medications for people with serious health conditions requiring complex therapies. These medications and therapies have very out-of-pocket rates, which in turn makes the specialty pharmacy a very costly business to start with, which requires huge amounts of investments and funding. The negligent government aid and initiatives are leading to the decline of these pharmacies.

Thus, the insufficient funding for specialty pharmacies may act as a challenge in the growth of Canada specialty pharmacy market.

Post COVID-19 Impact on Canada Specialty Pharmacy Market

The coronavirus pandemic has affected Canada's specialty pharmacy industry across four main areas: product sourcing and procurement, product launch and distribution, acquisition and access, and treatment and care management. Specialty pharmacies have risen to the occasion by working closely with federal and provincial government agencies to address challenges experienced by the healthcare system to combat the COVID-19 pandemic. These include exploring new ways of working, increasing testing capacity and results tracking for COVID-19, and ultimately working toward the development, manufacture, and delivery of safe and effective vaccines and treatment. Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple strategies and programs for the specialty pharmacy market.

Recent Development

• In March 2022, BioScript solutions and NeonMind announced the strategic partnership to expand the specialty clinic network for interventional psychiatry treatments. This partnership will leverage the BioScript solutions in an extensive national network of community-based infusion clinics to expand access to NeonMind's interventional psychiatry and unique treatment programs for Canadians

Canada Specialty Pharmacy Market Scope

Canada specialty pharmacy market is categorized into three segments, which are based on service type, type, and condition. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

• Service Type
  • Clinical services
  • Operational services
  • Other services

On the basis of service type, the Canada specialty pharmacy market is segmented into clinical services, operational services, and other services.

•  Type
  • Large pharmacy benefit manager (PBM)
  • Small-independent pharmacy service providers

On the basis of type, the Canada specialty pharmacy market has been segmented into large pharmacy benefit manager (PBM) and small-independent pharmacy service providers.

• Condition
  • Anemia
  • Cancer
  • HIV
  • Infertility
  • Multiple sclerosis
  • Rheumatoid arthritis
  • Growth hormone deficiencies
  • Hepatitis c virus
  • Hemophilia
  • Psoriasis
  • Pulmonary hypertension
  • Crohn's disease
  • Cystic fibrosis
  • Immune deficiency
  • Osteoarthritis
  • Juvenile idiopathic arthritis
  • Ulcerative colitis
  • Others

On the basis of condition, the Canada specialty pharmacy market has been segmented into anemia, cancer, HIV, infertility, multiple sclerosis, rheumatoid arthritis, growth hormone deficiencies, hepatitis C virus, hemophilia, psoriasis, pulmonary hypertension, Crohn's disease, cystic fibrosis, immune deficiency, osteoarthritis, juvenile idiopathic arthritis, ulcerative colitis, and others.

カナダの専門薬局市場の地域分析/洞察

カナダの専門薬局市場が分析され、市場規模の洞察と傾向が、上記のように国、サービスの種類、タイプ、条件別に提供されます。

カナダの専門薬局市場は、専門医薬品の需要の増加、流通チャネルの増加、慢性疾患の罹患率の増加により成長しており、市場の成長を促進すると予想されています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税の影響、貿易ルートも考慮されます。

競争環境とカナダの専門薬局市場シェア分析

カナダの専門薬局市場の競争状況では、競合他社ごとに詳細が提供されます。会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などの詳細が含まれます。上記のデータ ポイントは、専門薬局市場への会社の重点にのみ関連しています。

専門薬局市場で事業を展開している主要企業としては、McKesson Canada、Bayshore HealthCare、SRx Health、Sentrex Health Solutions、Sobeys Inc.、PHARMASAVE、Lovell Drugs、Create Compounding Ltd.、Dynasty Pharmacy、Resident Care Pharmacy、Pace Pharmacy、Northmount Pharmacy and Compounding Lab、Medicine Centre、riverviewguardian.ca、Brunskillpharmacy、Extend Pharmacy、Sherman Specialty Pharmacy、Quick Medicine、Allcures Pharmacy、Alpine Drug Mart IDA、PharmaChoiceAnchor Compounding Pharmacy、Andreen's Pharmacy、Balanced Health Integrative Pharmacy、Bains Pharmacy、Shoppers Drug Mart Specialty Health Network Inc.、MEDS などがあります。

SKU-69504